Infigratinib
Back to searchMolecule Structure
Scientific Name
Infigratinib
Description of the Drug
Infigratinib is an FGFR inhibitor used to treat locally advanced or metastatic cholangiocarcinoma in adults with a fibroblast growth factor receptor 2 (FGFR2) rearrangement.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB11886
http://www.drugbank.ca/drugs/DB11886
Brand Name(s)
Not Available
Company Owner(s)
Helsinn Healthcare Sa
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Fibroblast growth factor receptor | PROTEIN FAMILY | INHIBITOR | CHEMBL2095217 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL374435 |
| Human Metabolome Database | HMDB0247543 |
| DrugBank | DB11886 |
| PubChem: Thomson Pharma | 124359248 |
| PubChem | 53235510 |
| LINCS | LSM-1184 |
| Nikkaji | J3.268.564A |
| PDBe | 07J |
| BindingDB | 50355393 |
| EPA CompTox Dashboard | DTXSID70236238 |
| DrugCentral | 5459 |
| Brenda | 213446 |
| ChemicalBook | CB52589643 |
| Guide to Pharmacology | 7877 |
| ChEBI | 63451 |
| ZINC | ZINC000072105034 |
